ONE NEW HEALTH PLAN PERFORMANCE MEASURE RECOMMENDED FOR ENDORSEMENT

One HEALTH PLAN Performance Measure – for ENDORSEMENT

1. *Proportion of Days Covered Composite [Health Plan]* (PDC-CMP)

DESCRIPTION: The composite percentage of individuals ≥18 years of age who met the Proportion of Days Covered (PDC) threshold of 80% for diabetes medications, RAS antagonists, and statins during the measurement year.

This is a composite health plan performance measure that combines rates from the following component measures:

- Component 1: Proportion of Days Covered: Diabetes All-Class (PDC-DR)

  - The denominator includes individuals ≥18 years of age with ≥2 prescription claims for any diabetes medications on different dates of service in the treatment period.

  - The numerator includes individuals who met the PDC threshold of 80% during the measurement year.

  - Individuals in hospice care or with end stage renal disease (ESRD) during the measurement year, or with ≥1 prescription claims for insulin during the treatment period, are excluded.

- Component 2: Proportion of Days Covered: Renin Angiotensin System Antagonists (PDC-RASA)

  - The denominator includes individuals ≥18 years of age with ≥2 prescription claims for any RAS antagonists on different dates of service in the treatment period.

  - The numerator includes individuals who met the PDC threshold of 80% during the measurement year.

  - Individuals in hospice care or ESRD during the measurement year, or with ≥1 prescription claims for sacubitril/valsartan during the treatment period, are excluded.

- Component 3: Proportion of Days Covered: Statins (PDC-STA)

  - The denominator includes individuals ≥18 years of age with ≥2 prescription claims for any statin or statin combination product on different dates of service in the treatment period.

  - The numerator includes individuals who met the PDC threshold of 80% during the measurement year.

  - Individuals in hospice care or ESRD during the measurement year are excluded.

INTENDED USE: Performance measurement for health plans.

DATA SOURCE: Prescription claims, medical claims.

KEY POINTS:

- The PDC Composite was developed in response to stakeholder support for a summary indicator of adherence focused on medications for treatment of common chronic conditions.
  - o Integration of measures into a composite is a natural progression in the measurement lifecycle, allowing continued measurement of important quality concepts while reducing the total number of measures required in a given program.
  - o The PDC composite is anticipated to improve continued usability of PDC measures in quality programs.
- The PDC-CMP measure combines three individual component health plan measures to create a single measure to reflect medication adherence quality at the health plan level.
- The measure was tested by three PQA member organizations and in a 20% National Medicare sample. Testing included all lines of business (LOB), using data ranging from 2018 to 2021.
- Rates varied by LOB, ranging from 83%-85% for Medicare, 46%-60% for Medicaid, and 50% for commercial, indicating room for improvement.
- Reliability testing conducted as a ratio of signal-to-noise using the Adams beta binomial reliability methodology showed the measure is reliable,[1] exceeding the updated NQF threshold for reliability of 0.6.
  - o Medicare reliability ranged from 0.854 to 0.989
  - o Medicaid reliability ranged from 0.996 to 0.970
  - o Commercial reliability was 0.931
- The Measure Validity Panel (MVP) voted (2 strongly agree; 7 agree; 1 disagree; 0 strongly disagree; 0 abstain) that the PDC-CMP health plan performance measure has face validity.
- The Quality Metrics Expert Panel (QMEP) voted (21 yes; 5 no; 1 abstain) to recommend the PDC-CMP health plan performance measure to the PQA membership for endorsement consideration.
- If endorsed by PQA membership, this measure will be added to the 2023 PQA Measure Manual.

REFERENCES:

1. Adams JL. *The reliability of provider profiling: a tutorial*. 2009. Accessed September 20, 2021. https://www.rand.org/pubs/technical_reports/TR653.html